149 related articles for article (PubMed ID: 17061399)
1. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(9):1-4. PubMed ID: 17061399
[No Abstract] [Full Text] [Related]
2. Off-label uses of bevacizumab: breast and lung cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
[No Abstract] [Full Text] [Related]
3. Novel therapeutics for metastatic renal cell carcinoma.
Hutson TE; Figlin RA
Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
[TBL] [Abstract][Full Text] [Related]
4. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
5. Anti-angiogenic therapy in renal cell cancer.
Srinivasan R; Armstrong AJ; Dahut W; George DJ
BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
[TBL] [Abstract][Full Text] [Related]
6. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
Schrader AJ; Varga Z; Pfoertner S; Goelden U; Buer J; Hofmann R
BJU Int; 2006 Mar; 97(3):461-5. PubMed ID: 16469008
[No Abstract] [Full Text] [Related]
7. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
Eskens FA; Sleijfer S
Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy.
Joshi DD; Banerjee T
Pediatr Blood Cancer; 2008 Apr; 50(4):903-4. PubMed ID: 17486644
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
Wilkes GM
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
[No Abstract] [Full Text] [Related]
10. Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas.
Technol Eval Cent Assess Program Exec Summ; 2009 Oct; 24(4):1-3. PubMed ID: 20183930
[No Abstract] [Full Text] [Related]
11. [New targets and drugs for treatment of advanced renal cell carcinoma].
Rohde D
Aktuelle Urol; 2005 Apr; 36(2):125-30. PubMed ID: 15902572
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
Board RE; Thistlethwaite FC; Hawkins RE
Cancer Treat Rev; 2007 Feb; 33(1):1-8. PubMed ID: 17071006
[TBL] [Abstract][Full Text] [Related]
13. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in kidney cancer: new indication. Premature approval of this indication.
Prescrire Int; 2009 Feb; 18(99):10. PubMed ID: 19382401
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of loci in VEGF pathway genes in bevacizumab treatment.
Moroni M
Lancet Oncol; 2012 Jul; 13(7):659-60. PubMed ID: 22608782
[No Abstract] [Full Text] [Related]
16. FDA Approved Uses of Cabozantinib.
Leavitt J; Copur MS
Oncology (Williston Park); 2019 Sep; 33(9):. PubMed ID: 31571185
[No Abstract] [Full Text] [Related]
17. New agents for the treatment of renal cell carcinoma.
Tian GG; Dawson NA
Expert Rev Anticancer Ther; 2001 Dec; 1(4):546-54. PubMed ID: 12113087
[TBL] [Abstract][Full Text] [Related]
18. The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma.
Shah MA
Clin Adv Hematol Oncol; 2014 Apr; 12(4):239-46. PubMed ID: 25003353
[TBL] [Abstract][Full Text] [Related]
19. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
20. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma.
Gelmann EP
Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-65-S1-70. PubMed ID: 9045318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
